ReviewFrontiers in physiology2014
Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application.
Review in Frontiers in physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- COPD and Cardiovascular Diseases: Biomarker-Guided Stratification and Therapeutic Perspectives.Journal of clinical medicine · 2025Review
- Additive impact of chronic obstructive pulmonary disease (COPD) and cardiovascular disease(CVD) on all-cause and disease-Specific mortality: a longitudinal nationwide population-based study.BMC pulmonary medicine · 2025Article
- Life's Crucial 9 Score as a Novel Role for Chronic Obstructive Pulmonary Disease Screening.International journal of chronic obstructive pulmonary disease · 2025Article
- Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy.Life (Basel, Switzerland) · 2023Review
- Analysis of pathogenesis and drug treatment of chronic obstructive pulmonary disease complicated with cardiovascular disease.Frontiers in medicine · 2022Review
- Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis.Cell stem cell · 2020Article
- Article
- Cardiovascular disease and COPD: dangerous liaisons?European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Endothelial-Vascular Smooth Muscle Cells Interactions in Atherosclerosis.Frontiers in cardiovascular medicine · 2018Review
- DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases.Disease markers · 2018Article
- Cumulative Exposure to High-Sensitivity C-Reactive Protein Predicts the Risk of Cardiovascular Disease.Journal of the American Heart Association · 2017Article
- The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors.Experimental and therapeutic medicine · 2017Article
- The Vasodilatory Effects of Anti-Inflammatory Herb Medications: A Comparison Study of Four Botanical Extracts.Evidence-based complementary and alternative medicine : eCAM · 2017Article
- Effects of Optimism and Gratitude on Physical Activity, Biomarkers, and Readmissions After an Acute Coronary Syndrome: The Gratitude Research in Acute Coronary Events Study.Circulation. Cardiovascular quality and outcomes · 2016Observational
- Design and baseline data from the Gratitude Research in Acute Coronary Events (GRACE) study.Contemporary clinical trials · 2015Article
- Correlation between mimecan expression and coronary artery stenosis in patients with coronary heart disease.International journal of clinical and experimental medicine · 2015Article
- Puerarin Inhibits oxLDL-Induced Macrophage Activation and Foam Cell Formation in Human THP1 Macrophage.BioMed research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is the leading cause of death worldwide. Over the past two decades, it has been clearly recognized that atherosclerosis is an inflammatory disease of the arterial wall. Accumulating data from animal experiments have supported this hypothesis, however, clinical applications making use of this knowledge remain scarce. In spite of optimal interventional and medical therapy, the risk for recurrent myocardial infarction remains by about 20% over 3 years after acute coronary syndromes, novel therapies to prevent atherogenesis or treat atherosclerosis are urgently needed. This review summarizes selected potential molecular inflammatory targets that may be of clinical relevance. We also review recent and ongoing clinical trails that target inflammatory processes aiming at preventing adverse cardiovascular events. Overall, it seems surprising that translation of basic science into clinical practice has not been a great success. In conclusion, we propose to focus on specific efforts that promote translational science in order to improve outcome and prognosis of patients suffering from atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.